Case Study: Amylin Pharmaceuticals, Inc.

LSG served as exclusive financial advisor to Amylin in partnering Byetta with Eli Lilly and Co. in a $435 million transaction

• Byetta is a synthetic incretin mimetic for treatment of type-2 diabetes and potentially other indications
• We advised Amylin on the relative merits of each prospective partner candidate, the likely public market perception of a deal with the alternative candidates, as well as on the terms of the transaction
• Amylin chose to work with LSG because of our expertise in biotechnology, our financial analysis and transaction advisory skills and because we were willing to work with Amylin on a highly customized, consultative basis